Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Ram Sharma und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Androstenes, Brain Neoplasms, Glioblastoma, Steroid 17-alpha-Hydroxylase. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive and treatment-resistant brain tumor, necessitating novel therapeutic strategies. In this study, we present a mechanistic breakthrough by designing and evaluating a series of abiraterone-installed hydroxamic acids as potential dual inhibitors of CYP17A1 and HDAC6 for GBM treatment. We established the correlation of CYP17A1/HDAC6 overexpression with tumor recurrence and temozolomide resistance in GBM patients. Compound 12, a dual inhibitor, demonstrated significant anti-GBM activity in vitro, particularly against TMZ-resistant cell lines. Mechanistically, compound 12 induced apoptosis, suppressed recurrence-associated genes, induced oxidative stress and initiated DNA damage response. Furthermore, molecular modeling studies confirmed its potent inhibitory activity against CYP17A1 and HDAC6. In vivo studies revealed that compound 12 effectively suppressed tumor growth in xenograft and orthotopic mouse models without inducing significant adverse effects. These findings highlight the potential of dual CYP17A1 and HDAC6 inhibition as a promising strategy for overcoming treatment resistance in GBM and offer new hope for improved therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and…
- Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical Universi…
- Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan; TMU Research Center of Neuroscience, Taipei Medical Un…
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Drug Discovery and Development Indu…
Förderung
- National Science and Technology Council
Zitieren
APA
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P., & Hsu, T. I. (2024). Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216666
Vancouver
Sharma R, Chiang YH, Chen HC, Lin HY, Yang WB, Nepali K, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216666
BibTeX
@article{Sharma2024,
author = {Sharma, Ram and Chiang, Yung-Hsiao and Chen, Hsien-Chung and Lin, Hong-Yi and Yang, Wen-Bin and Nepali, Kunal and Lai, Mei-Jung and Chen, Kai-Yun and Liou, Jing-Ping and Hsu, Tsung-I},
title = {Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216666}
}
EUVIMED